What is ARIA CV?
ARIA CV is a pioneering medical technology firm dedicated to the development of novel implantable devices designed to address the critical needs of patients with pulmonary hypertension. Unlike traditional interventions that rely on batteries, pumps, or complex electronics, the company's flagship solution utilizes a unique mechanical design consisting of a reservoir and a balloon connected by a conduit. This system operates entirely through the natural motion of the heart, offering a passive, durable, and highly innovative alternative to existing therapeutic modalities.
The company operates at the intersection of cardiovascular health and mechanical engineering, targeting healthcare providers and clinical researchers who are actively seeking more effective, long-term solutions for pulmonary hypertension. By eliminating the risks associated with electronic failure or power source depletion, ARIA CV is positioning its technology as a potential standard-of-care advancement in the medical device sector.
How much funding has ARIA CV raised?
ARIA CV has raised a total of $40.2M across 3 funding rounds:
Series A
$7.8M
Series B
$31M
Private Equity
$1.4M
Series A (2015): $7.8M with participation from Cedar Point Capital, BioStar Capital, Broadview Ventures, and Catalyst Health Ventures
Series B (2020): $31M, investors not publicly disclosed
Private Equity (2025): $1.4M, investors not publicly disclosed
Key Investors in ARIA CV
Cedar Point Capital
Cedar Point Capital is a Chicago-based investment management firm that utilizes a tactical and strategic portfolio philosophy to enhance returns through the inclusion of alternative asset sleeves.
BioStar Capital
BioStar Capital is a specialized healthcare investor that leverages clinical expertise and medical thought leadership to support transformative medical device innovations.
Broadview Ventures
Broadview Ventures is an impact-focused investment firm dedicated to accelerating the development of innovative technologies for the diagnosis and treatment of cardiovascular disease and stroke.
What's next for ARIA CV?
With the successful closure of this major enterprise-level funding, ARIA CV is well-positioned to transition from clinical investigation to broader market adoption. The strategic focus will likely center on scaling manufacturing capabilities and expanding the scope of its clinical trials to demonstrate long-term efficacy and safety. As the company continues to refine its device, it remains a key player for stakeholders interested in the future of cardiovascular health and the integration of passive mechanical solutions into modern clinical practice. The firm's ability to attract high-caliber institutional backing suggests a robust roadmap for regulatory approval and commercialization in the coming years.
See full ARIA CV company page
